Chronic renal failure primary prevention

Chronic renal failure Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Chronic renal failure from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Chronic renal failure primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Chronic renal failure primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Chronic renal failure primary prevention
CDC on Chronic renal failure primary prevention
Chronic renal failure primary prevention in the news
Blogs on Chronic renal failure primary prevention
Directions to Hospitals Treating Chronic renal failure
Risk calculators and risk factors for Chronic renal failure primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: :Aarti Narayan, M.B.B.S [2],Sargun Singh Walia M.B.B.S.[3]

Overview

Effective measures for the primary prevention of chronic renal failure include treatment of reversible exacerbants such as volume depletion, nephrotoxins, urinary tract obstruction and other causes.

Primary Prevention

Effective measures for the primary prevention of chronic renal failure include:

• Treatment of reversible exacerbants
  • Volume Depletion
    • May be subtle
    • Autoregulation impaired with DM, hypertension, CRI--decreases GFR with mild volume depletion
      • Careful trial of volume repletion may--return of baseline renal function
    • (Increase dietary Na, reduce diuretic dosing)
  • Nephrotoxins
    • NSAIDS
      • Most toxic in setting of volume depletion, CHF, diuretic use
      • Reduce prostaglandin (PG) synthesis--unopposed vasoconstriction with decreased GFR
      • Can also cause ATN (acute tubular necrosis)
    • Aminoglycosides
      • Nonoliguric ARF typically occurs at 7-10 days
      • Increased risk with older patients, prolonged therapy and greater total dose
    • IV contrast
      • ARF usually occurs within 24-48 hours of dye administration
      • Peak Cr after 5-7 days with return to baseline at 10-14 days
      • Risk ARF increased with DM and higher volume of dye
      • Note: certain meds increase serum Cr (via inhibiting Cr secretion or interfering with assay) without changing GFR, e.g. cimetidine, trimethoprim (TMP), cefoxitin, flucytosine; BUN will not rise because GFR is preserved
  • Urinary Tract Obstruction
    • Most commonly due to prostatic hypertrophy in men
  • Other causes:
    • Nephrolithiasis
    • Tumor
    • Neurogenic bladder
    • Results in reduced GFR and impaired tubular function
    • Consider ultrasound, urologic evaluation